• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Tonix Pharmaceuticals Holding Corp.

    10/31/25 11:31:40 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNXP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Tonix Pharmaceuticals Holding Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    890260839

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    890260839


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    57,410.00
    7Sole Dispositive Power

    496,907.00
    8Shared Dispositive Power

    60,050.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    556,957.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.35 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tonix Pharmaceuticals Holding Corp
    (b)Address of issuer's principal executive offices:

    509 Madison Avenue, Suite 306, New York, NY, 10022
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    890260839
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    556957
    (b)Percent of class:

    6.35  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    57410

     (iii) Sole power to dispose or to direct the disposition of:

    496907

     (iv) Shared power to dispose or to direct the disposition of:

    60050

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/31/2025
    Get the next $TNXP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNXP

    DatePrice TargetRatingAnalyst
    4/18/2022Outperform
    Noble Capital Markets
    More analyst ratings

    $TNXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Taylor Carolyn E. bought $15,061 worth of shares (418 units at $36.03) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/21/25 5:22:56 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Treco James bought $9,000 worth of shares (250 units at $36.00) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/20/25 4:15:15 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunter James Randolph Jr

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    6/13/25 4:42:46 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Taylor Carolyn E. bought $15,061 worth of shares (418 units at $36.03) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/21/25 5:22:56 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Treco James bought $9,000 worth of shares (250 units at $36.00) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/20/25 4:15:15 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Lederman Seth bought $86,200 worth of shares (4,000 units at $21.55), increasing direct ownership by 80,000% to 4,005 units (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    5/15/25 5:08:40 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNXP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Tonix Pharmaceuticals Holding Corp.

    SCHEDULE 13G - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    10/31/25 11:31:40 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    10/27/25 7:00:38 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    10/22/25 7:05:37 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $TNXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Noble Capital Markets initiated coverage on Tonix Pharma

    Noble Capital Markets initiated coverage of Tonix Pharma with a rating of Outperform

    4/18/22 9:20:45 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners resumed coverage on Tonix Pharmaceuticals with a new price target

    Alliance Global Partners resumed coverage of Tonix Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.00 previously

    2/25/21 7:39:46 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

    Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026   Novel immunomodulatory regimen designed to reduce calcineurin inhibitor exposure and improve outcomes Dimeric Fc-modified mAb TNX-1500 selectively targets cell-associated CD40L with once-monthly dosing CHATHAM, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial biotechnology company, today announced a collaboration with Massachusetts General Hospital (MGH), a founding member of Mass General Brigham (MGB) to conduct a Phase 2 clinical tr

    11/4/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

    CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biopharmaceutical company announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe 2025, being held November 3–5, 2025, in Vienna, Austria. The Company's presentation will take place on Tuesday, November 4, at 3:00 p.m. CET in Presenting Company Theater 1 at the Vienna Congress and Convention Center. Dr. Lederman will present an overview of Tonix's strategy and pipeline, highlighting near-term clinical, regulatory, and commercial milestones. To schedule a meeting with the

    10/28/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

    Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia CHATHAM, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial biotechnology company presented data on Tonmya™, which was investigated as TNX-102 SL, at the 2025 American College of Rheumatology (ACR) Converg

    10/27/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:40:17 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    10/16/24 9:01:20 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNXP
    Financials

    Live finance-specific insights

    View All

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monday August 18, 2025 at 8:30 AM ET CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administratio

    8/15/25 3:44:52 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

    Strategic Acquisition Helps Build Tonix's Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), Indicated for the Treatment of Acute Migraine in Adults, Complements Tonix's Current Intranasal Clinical Development Program of TNX-1900 for Migraine Prevention CHATHAM, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix Pharmaceuticals or Tonix), a biopharmaceutical company, and its wholly-owned commercialization subsidiary Tonix Medicines, Inc. (Tonix Medicines), today announced it

    7/3/23 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

    Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Planned Interim Analyses of TNX-102 SL in Phase 3 Fibromyalgia Study and Phase 2 Long COVID Study Expected Second Quarter 2023 Advanced Development Center in Dartmouth, Mass. and Infectious Disease Research and Development Facility in Frederick, Md. Operational Cash and Cash Equivalents Totaled Approximately $140 Million at September 30, 2022 CHATHAM, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the

    11/7/22 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNXP
    Leadership Updates

    Live Leadership Updates

    View All

    Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

    Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years US Launch of Tonmya expected in the fourth quarter of 2025 CHATHAM, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the appointment of Ganesh Kamath as Head of Market Access

    9/30/25 8:30:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors

    Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year CHATHAM, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of

    6/13/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

    Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene Served on Celgene's Executive Committee and played a key leadership role in the BMS transaction, the integration of Celgene into BMS, and the divestiture of Otezla® to Amgen Appointment marks a key addition as Tonix readies for the potential approval of TNX-102 SL for the management of fibromyalgia next quarter CHATHAM, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical compa

    5/14/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care